| IN TR ODUC TION
Immune-mediated hemolytic anemia (IMHA) is a common cause of anemia in dogs. 1 The case fatality rate for canine IMHA approach 50%-70%, 2 and one of the most common cause of death is thromboembolic disease. The true incidence of thromboembolism in dogs with IMHA is unknown, but has been estimated to be as high as 50%-80%. 3 The exact mechanism of thrombus formation is unknown and probably multifactorial: dogs with IMHA have been shown to have an increase in hyperactive platelets, 4 procoagulant microparticles, 5 and intravascular tissue factor expression. 6 When activated, platelets release several vasoactive molecules that contribute to a hypercoagulable state and predisposition to thromboembolism. Cyclosporine has become a popular drug for the treatment of IMHA in dogs. 8 In dogs, as in humans, 9 ,10 administration of cyclosporine is associated with a significant increase in thromboxane A 2 synthesis, especially at the time of peak blood drug concentrations in dogs receiving immunosuppressive dosages of cyclosporine. 11, 12 Thromboxane A 2 , which is primarily produced by activated platelets, triggers vasoconstriction, and enhances platelet activation and aggregation, which decreases blood flow, promotes coagulation, and could predispose patients to excessive thrombus formation. 13 In human renal transplant recipients, patients treated with cyclosporine have increased thromboxane A 2 synthesis, and an associated increased rate of thrombus formation within the renal parenchyma when compared with patients receiving azathioprine. 10 Azathioprine, mycophenolate mofetil, and leflunomide are other potent immunosuppressive agents commonly used to treat dogs with IMHA. 8, 14 In human transplant patients receiving azathioprine, thromboxane synthesis does not increase 10 and, in mice treated with mycophenolate mofetil, there is actually a reduction in thromboxane synthesis. 15 The effects of leflunomide on thromboxane synthesis has not been determined. Although previous studies have evaluated the effects of cyclosporine on the hemostatic system in dogs, 11, 12 comparable studies evaluating the effects of other immunosuppressive drugs on hemostasis have either not been performed in dogs or have measured only a limited range of drugs or hemostatic indices. [16] [17] [18] [19] [20] In dogs, the effects of azathioprine, mycophenolate mofetil, and leflunomide on the hemostatic system are currently almost completely unknown.
Because cyclosporine induces thromboxane synthesis in dogs, with an associated concern about potentially predisposing hypercoagulable dogs to thromboembolic complications, alternative immunosuppressive agents such as azathioprine, mycophenolate mofetil, and leflunomide have the potential to be safer therapeutic options. However, the effects of these medications on the canine hemostatic system are essentially unknown, and there is a possibility that, as with cyclosporine, these drugs could also be prothrombotic. followed by a recovery period of at least 21 days between dosing. In previous cyclosporine studies, changes in thromboxane production were seen within one week of commencing the drug, and had returned to pretreatment values within 2 weeks of discontinuing the medications. 11, 12 After the recovery period, the dogs switched groups, and the study was continued until all dogs had received all medications.
For all medication groups, blood and urine samples were collected on day 0 (before drug administration) and on day 7 of drug administra- Franklin Lakes, New Jersey) and 1 tube containing EDTA (manual platelet count). Two of the citrate tubes were used for aggregometry, 1 tube was used for PFA-100 and SonoClot analysis, and the final tube was used for the PT and aPTT. For the PFA-100 and SonoClot, the tube of blood was held at room temperature without disturbance.
Immediately before analysis, the tube was inverted 3 times and the blood was inserted into the instruments via pipetting. Urine was collected by an ultrasound-guided cystocentesis using a 22-gauge 1.5 inch needle with a 6 mL syringe. The volume of urine collected varied between 2 and 5 mL, and urine was stored at 2808C for later analysis.
There were no notable technical problems encountered with venipunctures in individual animals that would be expected to adversely influence the results, and the collection of additional blood samples was not required.
| Optical platelet aggregometry
To create platelet-rich plasma (PRP), whole blood collected into 3.2% Duluth, Georgia) was used initially to ensure normal platelet function in each dog before enrolment in the study, and the collagen/epinephrine cartridge (PFA Collagen/EPI Test Cartridge, Siemens Healthcare Diagnostics) was used during the study to assess drug-associated platelet dysfunction. Two collagen/epinephrine cartridges were analyzed concurrently, and the closure times were averaged. All samples were analyzed within 2 hours of collection.
| Viscoelastometry (SonoClot)
The SonoClot (SonoClot, Sienco Inc, Arvada, Colorado) uses a viscoelastometric system to detect mechanical changes that occur within a whole blood sample as it clots, and provides information on coagulation, fibrin gel formation, and clot retraction. The SonoClot contains a tubular probe that oscillates within a blood sample and detects the resistance to motion that the probe encounters as the sample clots, generating a clot signal. Clotting was triggered using the gbACT Kit All samples were analyzed within 3 hours of collection.
| Urine 11-dehydro-thromboxane B 2
Urinary 11-dTXB 2 (a stable thromboxane A 2 metabolite) concentration was measured using an ELISA kit (11-dehydro-thromboxane B2 EIA kit-Monoclonal, Cayman Chemical Co, Ann Arbor, Michigan) that has been previously validated in dogs. 27, 28 For analysis, samples were thawed to room temperature, diluted with the assay buffer, and handled according to the manufacturer's instructions. Samples were analyzed in triplicate, analyzed at a wavelength of 412 nm using a plate reader (SpectraMax M5 Multi-Mode Microplate Reader, Molecular
Devices, Sunnyvale, California), and reported in picograms per milliliter of urine. Urine creatinine concentration was measured using a biochemistry analyzer (ACE Alera, Clinical Chemistry System, Alfa
Wasserman, Inc, West Caldwell, New Jersey) and used to calculate a urinary 11-dTXB 2 -to-creatinine ratio.
| Urine 6-keto-prostaglandin F 1a
Urinary 6-keto-prostaglandin F 1a (6-keto-PGF 1a , a stable prostacyclin metabolite) concentration was analyzed using an ELISA kit (6-ketoprostaglandin-F1a EIA, Cayman Chemical Co) that has undergone analytic validation by the manufacturer and has been used previously in dogs. 29 Using a similar technique as described with urinary 11-dTXB 2 , urinary 6-keto-PGF 1a was analyzed according to the manufacturer's instructions. Samples were analyzed in triplicate, averaged, and reported in picograms per milliliter of urine. Urine creatinine
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concentration was measured to calculate a urinary 6-keto-PGF 1a -tocreatinine ratio. 
| Additional tests of hemostasis

| Statistical analysis
The 
| R E SULTS
| Optical aggregometry
Mean optical aggregometry maximum amplitudes, activated with ADP and collagen, are presented in Table 1 . When ADP was used as an agonist, the maximum amplitude was significantly (P 5 .002) lower than pretreatment values after leflunomide administration. There were no other differences in amplitude after treatment with any remaining immunosuppressive agent (P 5 .114). When collagen was used as an agonist, there were no differences from pretreatment values after treatment with any of the immunosuppressive medications (P 5 .173). Results labeled "*" illustrate significant (P .05) differences from the respective day 0 sample.
| Platelet function analysis
Before commencement of the study, the mean PFA-100 closure time using the collagen/ADP cartridge was 68.6 6 18.1 seconds (mean 6 standard deviation), and all dogs had results within previously reported reference ranges. 21, 22 Mean PFA-100 closure times using the collagen/ epinephrine cartridge are presented in Table 1 . When compared with day 0 (pretreatment), there was a significant (P 5 .012) increase in closure time on day 7 of leflunomide administration. There were no significant differences in closure times between days 0 and 7 for the remaining immunosuppressive agents (P 5 .220).
| Viscoelastometry (SonoClot)
ACT, ClotRate, and platelet function results are presented in Table 1 .
For all immunosuppressive agents, there were no significant differences in any of the three measurements between days 0 and 7 (P 5 .340).
| Urine 11-dehydro-thromboxane B 2
Urine 11-dTXB 2 -to-creatinine ratios for all immunosuppressive agents on days 0 and 7 are represented in Figure 1 . Urine could not be collected from one dog on day 0 before azathioprine treatment and from one dog on day 7 during mycophenolate administration. There was not a significant day by medication interaction (P 5 .419) or medication effect (P 5 .614). However, compared with day 0, there was a significant (P 5 .001) increase in the 11-dTXB 2 -to-creatinine ratio on day 7, when adjusted for the effect of medication. During cyclosporine, leflunomide, and prednisone administration, the urine 11-dTXB 2 -tocreatinine ratio increased in 8, 7, and 6 dogs, respectively. (Supplemental Figures 1-5 ).
| Urine 6-keto-prostaglandin F 1a
Urine 6-keto-PGF 1a -to-creatinine ratios for all medications on days 0 and 7 are represented in Figure 2 . Compared with day 0, there was a significant (P < .001) increase in the 6-keto-PGF 1a -to-creatinine ratio on day 7 during cyclosporine administration. Compared with day 0, there were no significant differences from pretreatment in the 6-keto-PGF 1a -to-creatinine ratio for the remaining immunosuppressive medications (P 5 .935).
| Additional tests of hemostasis
Platelet count, PT, and aPTT results are presented in Table 1 . Compared with day 0, there was a significant (P < .001) decrease in the PT value on day 7 for the prednisone group. Compared to day 0, there were no significant differences in the PT on day 7 for the remaining immunosuppressive medications (P 5 .910). For all medications, there were no significant differences between days 0 and 7 for the platelet count and aPTT (P 5 .151).
| D ISC USSION
In dogs with IMHA, cyclosporine is widely used as an adjunctive treatment to corticosteroids. 8 As has been reported in humans, cyclosporine, especially at the time of peak blood drug concentrations, will increase synthesis of thromboxane in dogs in a dose-dependent manner. 11, 12 Our study demonstrated there was a significant increase in thromboxane synthesis after drug administration.
Additional studies in a greater number of animals would be required to further explore the potential effects of leflunomide and prednisone on thromboxane synthesis in dogs. Unlike cyclosporine, increases in thromboxane with prednisone and leflunomide were inconsistent between dogs, and some dogs had a decrease in thromboxane production. Given, the known anti-inflammatory properties of prednisone, the increase in thromboxane concentration was unexpected, because glucocorticoids are known to inhibit the conversion of arachidonic acid into eicosanoids, which would be expected to lead to a reduction in prostaglandin and thromboxane synthesis. The administration of a glucocorticoid is associated with an increase in thromboxane synthesis in dogs. 30 Thromboxane A 2 increases blood stasis and promotes hemostasis by initiating vasoconstriction and causing platelet activation. Platelets are the most important source of thromboxane A 2 , although other cells, such as leukocytes and endothelial cells, can also synthesize this eicosanoid. 27 Once synthesized, thromboxane A 2 is rapidly converted to several stable metabolites, such as 11-dTXB 2 and 2,3-dinor-thromboxane B 2 , that are eliminated in the urine and considered to be reliable markers of systemic thromboxane A 2 production. 27, 28, 31 Because only about 30% of dogs have platelets that are sensitive to the effects of thromboxane, 32,33 drug-induced thromboxane synthesis would not be expected to reliably activate platelets in all dogs. Thromboxane, even if it does not affect all canine platelets, could however still stimulate vasoconstriction and predispose to thrombus formation.
Prostacyclin, which primarily originates from the vascular endothelium, inhibits platelet activation and causes vasodilation, thereby countering the prothrombotic properties of thromboxane. 34 In a manner similar to thromboxane A 2 , prostacyclin is also rapidly converted to stable metabolites such as 6-keto-PGF 1a , and excreted in the urine. 35 Our study demonstrated that urinary prostacyclin concentration is significantly increased in dogs receiving immunosuppressive doses of cyclosporine. This increase in prostacyclin synthesis could potentially counteract and minimize the prothrombotic effects of cyclosporineinduced thromboxane synthesis.
In our study, similar to previous studies, 11, 12 properties. An in vitro study involving mice, a leflunomide metabolite analog, LFM-A13, inhibited platelet shape change, degranulation, and aggregation after stimulation with collagen as an agonist. 36 There are currently no published studies that have investigated the effects of leflunomide metabolites on platelet aggregation in dogs.
In our study, by day 7 of administration of prednisone, PT was statistically shorter than pretreatment values, but remained within the normal reference interval. A decrease in PT below reference interval has been associated with a greater predisposition to thrombus formation in dogs, but it is not certain if a decrease in PT that does not drop outside of reference ranges is associated with the same predisposition. 37 There were no significant changes in any of the remaining hemostatic indices that were measured during prednisone administration. The results of our study are in contrast to previous studies that have demonstrated changes in multiple indices of hemostasis during prednisone treatment. 16, 17 In one previous study, in contrast to our study, platelet aggregation with ADP as an agonist increased when dogs were administered immunosuppressive dosages of prednisone. 17 Unfortunately, a direct comparison between this previous study and our study cannot be made because differences in the aggregometry protocol and ADP concentration used do not provide consistent conditions to allow assessment of the effects of prednisone on platelet aggregation. Previous studies utilizing thromboelastography have suggested that healthy dogs became hypercoagulable while receiving glucocorticoid treatment. 16, 18 Although thromboelastography was not used in our study, a very similar method, viscoelastometry, was used, and no significant differences before and after treatment with prednisone were detected. A potential explanation for the difference between the previous studies and our study is that thromboelastography could be more sensitive than viscoelastometry to the effects of glucocorticoids on hemostatic indices and clot strength. Additional research would be required to determine the exact relationship between prednisone and predisposition to thrombosis in dogs.
Compared with pretreatment values, there were no significant difference with any test of hemostasis for either azathioprine or mycophenolate mofetil. Because both azathioprine and mycophenolate mofetil have similar mechanisms of action, it was expected that these medications would have similar results. The results of our study are similar to previous studies performed in humans that did not identify a significant change in measures of hemostasis during treatment with azathioprine or mycophenolate mofetil. 9, 10, 38 There were several limitations to our study. Firstly, healthy dogs with no evidence of hypercoagulability were used in our study. Hypercoagulable dogs with hyperactive platelets might react differently to immunosuppressive medications than healthy animals. Secondly, although a sample size calculation was performed before study initiation, it is possible that with more dogs enrolled in the study, the results would have been different. Thirdly, while our study evaluated the effects of immunosuppressive treatment on measurements of hemostasis after 7 days of drug administration, most clinical patients that receive immunosuppressive agents require chronic treatment that persists for far longer than 1 week. The effects of the evaluated immunosuppressive agents on the hemostatic system could be different during chronic treatment.
Additional study limitations were associated the platelet function assays used. Firstly, although our study used a number of tests that 
